超越眼部:替妥木单抗对甲状腺皮肤病是否有效?
本文通过5例严重胫前黏液性水肿合并甲状腺眼病患者的病例系列及文献复习,评估IGF-1R抑制剂替妥木单抗对甲状腺皮肤病的疗效。所有患者皮肤增厚均显著改善且功能能力提升,但出现听力下降、肌肉痉挛、疲劳及一例需停药的严重胃肠道事件,复发者再次治疗仍有效。
要点
- 替妥木单抗对严重胫前黏液性水肿显示临床改善,包括皮肤增厚消退。
- 治疗中可出现听力下降、肌肉痉挛、疲劳及需停药的严重胃肠道事件。
- 疾病复发者再次接受替妥木单抗治疗仍可应答。
核心结论
- 替妥木单抗治疗胫前黏液性水肿显示出有希望的疗效,但需进一步研究确认其持久性和安全性。
研究设计与样本
- 病例系列纳入5例严重胫前黏液性水肿合并甲状腺眼病患者并接受替妥木单抗治疗,同时进行文献病例复习。
主要发现
- 所有患者均出现显著临床改善,包括皮肤增厚消退和功能能力提升。
- 副作用包括轻度听力下降、肌肉痉挛和疲劳。
- 一例患者发生需停药的严重胃肠道事件,复发者再次治疗后仍应答。
临床怎么用
- 对严重胫前黏液性水肿合并甲状腺眼病患者,替妥木单抗可能作为治疗选择,但需监测胃肠道及听力等不良反应。
局限性
- 病例系列样本量小,需进一步研究确认疗效持久性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretibial dermopathy (PTD) is a rare, disfiguring manifestation of Graves' disease. The shared pathophysiology with thyroid eye disease (TED), centered on fibroblast activation via a thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor (IGF-1R) complex, provides a strong rationale for using the IGF-1R inhibitor, teprotumumab. METHODS: We present a case series of five patients with severe PTD and concomitant TED who were treated with teprotumumab. A review of reported cases in the literature was also conducted. RESULTS: All patients experienced significant clinical improvement, including regression of skin thickening as well as enhanced functional capacity. Side effects included mild hearing loss, muscle cramps, and fatigue. One patient experienced a severe gastrointestinal event requiring treatment discontinuation, while those experiencing a recurrence of PTD, responded to a second course of therapy. CONCLUSIONS: Teprotumumab showed promising efficacy in the treatment of PTD. Further studies are needed to confirm its durability and safety.
引用
- Hamadi D, Saad-Omer S, Toro-Tobon D, et al. Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy? Thyroid. 2026. PMID: 41791882. doi:10.1177/10507256251414948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。